
Psychemedics Corporation PMD
Quarterly report 2024-Q3
added 11-12-2024
Psychemedics Corporation Book Value 2011-2026 | PMD
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Psychemedics Corporation
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.67 M | 10.8 M | 12.2 M | 12.5 M | 16.8 M | 18.7 M | 18.6 M | 15.6 M | 11.7 M | 12.8 M | 12.3 M | 11.2 M | 11 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 18.7 M | 6.67 M | 13.2 M |
Quarterly Book Value Psychemedics Corporation
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.45 M | 5.74 M | 6.28 M | 6.67 M | 7.43 M | 9.13 M | 10.2 M | 10.8 M | 11.7 M | 11.9 M | 12.5 M | 12.2 M | 14 M | 13.1 M | 12.8 M | 12.5 M | 12.5 M | 12.5 M | 12.5 M | 16.8 M | 16.8 M | 16.8 M | 16.8 M | 18.7 M | 18.7 M | 18.7 M | 18.7 M | 18.6 M | 18.6 M | 18.6 M | 18.6 M | 15.6 M | 15.6 M | 15.6 M | 15.6 M | 11.7 M | 11.7 M | 11.7 M | 11.7 M | 12.8 M | 12.8 M | 12.8 M | 12.8 M | 12.3 M | 12.3 M | 12.3 M | 12.3 M | 11.2 M | 11.2 M | 11.2 M | 11.2 M | 11 M | 11 M | 11 M | 11 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 18.7 M | 5.45 M | 13 M |
Book Value of other stocks in the Diagnostics research industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M | ||
|
Charles River Laboratories International
CRL
|
3.21 B | $ 168.22 | -3.26 % | $ 8.34 B | ||
|
Agilent Technologies
A
|
5.39 B | $ 114.84 | -0.55 % | $ 34.9 B | ||
|
Castle Biosciences
CSTL
|
456 M | $ 24.73 | -0.44 % | $ 687 M | ||
|
Danaher Corporation
DHR
|
83.5 B | $ 192.12 | 0.53 % | $ 137 B | ||
|
DexCom
DXCM
|
2.75 B | $ 63.21 | 1.59 % | $ 24.7 B | ||
|
Aspira Women's Health
AWH
|
-6.93 M | - | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
8.86 M | - | -13.05 % | $ 7.29 M | ||
|
Fulgent Genetics
FLGT
|
1.13 B | $ 16.42 | -2.38 % | $ 496 M | ||
|
Check-Cap Ltd.
CHEK
|
-1.45 M | - | - | $ 9.42 M | ||
|
Guardant Health
GH
|
-99.3 M | $ 89.66 | -4.44 % | $ 11.2 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
16.7 M | - | - | $ 562 M | ||
|
Akumin
AKU
|
141 M | - | -17.87 % | $ 25.9 M | ||
|
ICON Public Limited Company
ICLR
|
9.52 B | $ 109.62 | -4.0 % | $ 9.04 B | ||
|
CareDx, Inc
CDNA
|
303 M | $ 17.82 | -2.68 % | $ 950 M | ||
|
Illumina
ILMN
|
6.3 B | $ 127.74 | 0.28 % | $ 20.3 B | ||
|
Burning Rock Biotech Limited
BNR
|
1.85 B | $ 16.3 | 0.62 % | $ 175 M | ||
|
IQVIA Holdings
IQV
|
6.63 B | $ 170.72 | -1.47 % | $ 29.3 B | ||
|
Accelerate Diagnostics
AXDX
|
-22.3 M | - | -61.36 % | $ 2.46 M | ||
|
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 274.46 | 0.27 % | $ 22.8 B | ||
|
Lantheus Holdings
LNTH
|
1.09 B | $ 75.89 | -0.28 % | $ 5.12 B | ||
|
Global Cord Blood Corporation
CO
|
4.88 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
132 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
16.4 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
548 M | - | 0.12 % | $ 80.1 M | ||
|
Exact Sciences Corporation
EXAS
|
2.4 B | - | - | $ 19.8 B | ||
|
Medpace Holdings
MEDP
|
459 M | $ 496.0 | -0.47 % | $ 14.3 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
1.32 B | - | - | $ 10.7 B | ||
|
Mettler-Toledo International
MTD
|
-23.6 M | $ 1 266.63 | 0.53 % | $ 26.1 B | ||
|
Myriad Genetics
MYGN
|
368 M | $ 4.67 | -1.68 % | $ 432 M | ||
|
ENDRA Life Sciences
NDRA
|
2.26 M | $ 4.74 | 1.07 % | $ 3.73 M | ||
|
NeoGenomics
NEO
|
837 M | $ 8.02 | 0.25 % | $ 1.03 B | ||
|
Neogen Corporation
NEOG
|
2.07 B | $ 9.56 | 1.59 % | $ 2.07 B | ||
|
DermTech
DMTK
|
57.2 M | - | -11.32 % | $ 2.94 M | ||
|
National Research Corporation
NRC
|
14 M | $ 17.33 | 0.99 % | $ 388 M | ||
|
Natera
NTRA
|
706 M | $ 204.87 | -1.5 % | $ 20.2 B | ||
|
Biodesix
BDSX
|
20.9 M | $ 15.36 | 1.92 % | $ 1.99 B | ||
|
Enzo Biochem
ENZ
|
56.1 M | - | -8.98 % | $ 14.8 K | ||
|
Pacific Biosciences of California
PACB
|
5.35 M | $ 1.42 | 5.97 % | $ 426 M | ||
|
Koninklijke Philips N.V.
PHG
|
11 B | $ 27.2 | 0.33 % | $ 20 B | ||
|
Precipio
PRPO
|
14.6 M | $ 25.98 | 1.64 % | $ 41.7 M | ||
|
Personalis
PSNL
|
203 M | $ 6.58 | - | $ 390 M | ||
|
RadNet
RDNT
|
1.36 B | $ 55.06 | 0.49 % | $ 4.14 B | ||
|
Senseonics Holdings
SENS
|
61 M | $ 6.69 | -3.04 % | $ 279 M | ||
|
Sotera Health Company
SHC
|
606 M | $ 14.87 | -0.6 % | $ 4.22 B | ||
|
Heska Corporation
HSKA
|
422 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
5.39 M | - | -20.0 % | $ 1.06 M | ||
|
Soleno Therapeutics
SLNO
|
450 M | $ 52.25 | 32.31 % | $ 2.66 B | ||
|
Neuronetics
STIM
|
26.2 M | $ 1.76 | 15.79 % | $ 116 M | ||
|
Thermo Fisher Scientific
TMO
|
110 B | $ 488.19 | -0.67 % | $ 184 B |